Tag Archive for: radioligand therapy
Phase 1/2 trial: Novel rhPSMA Therapy Targets Advanced Prostate Cancer With Precision
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxFutureChem Launches Phase 3 Trial for Novel PSMA-Targeted Radiopharmaceutical FC705
/in Clinical Trial, Metastatic, Phase 3/by MaxSECuRE Trial Update: Promising Results in Metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxThe Phase 1 ACCEL Trial: Actinium-225-PSMA-62
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPioneering Korean Trial Combines Radioligand Therapy and Immunotherapy for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxEmerging Radiopharmaceuticals for Low PSMA-Expressing Prostate Cancer: 67Cu-SAR-bisFAP and 67Cu-SAR-bombesin
/in Clinical Trial, Metastatic, Phase 1/by MaxPromising Results for 177Lu-PSMA-I&T in Prostate Cancer Treatment
/in Clinical Trial, Metastatic, Phase 3/by MaxPositive Phase 1 Data Supports Phase 2 of 177Lu rhPSMA-10.1 for mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 2: Iodine-131 PSMA Radioligand with Enzalutamide Shows Promise in ARROW trial for metastatic castration-resistant prostate cancer (mCRPC)
/in Clinical Trial, Metastatic, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 1 Trial: IL‑18–Armored STEAP1 CAR T Cells for Metastatic Castration‑Resistant Prostate Cancer September 7, 2026
- Newsletter 36/2026 September 6, 2026
- De‑escalation therapy in metastatic prostate cancer: can some men safely stop ADT + ARPI after a deep response? September 4, 2026
- Phase 3 Trial Tests a New B7-H3 Strategy in Advanced Prostate Cancer September 3, 2026